The sensitive and accurate detection of microRNA (miRNA) has meaningful values for clinical diagnosis application as an early stage of tumor markers. Herein, a novel photoelectrochemical (PEC) biosensor was developed for the ultrasensitive and highly selective detection of microRNA-122 (miRNA-122) based on a direct Z-scheme heterojunction of Zn vacancy-mediated CdS/ZnS (CSZS-V). Impressively, the prepared Z-scheme heterojunction nanocomposite with defect level properties could make the photogenerated charges stay at the Zn vacancy defect levels and combine photogenerated holes in the valence bands of CdS, thus significantly achieving a better charge carrier separation efficiency and broadening the absorption of visible light and demonstrating 5-8 times enhancement of PEC response compared to single-component materials. Simultaneously, an exonuclease III (Exo-III)-assisted signal amplification strategy and a strand displacement reaction were combined to improve the conversion efficiency of the target and further increase the detection sensitivity. More importantly, the elaborated biosensor showed ultrasensitive and highly specific detection of the target miRNA-122 over a wide linear range from 10 aM to 100 pM with a low detection limit of 3.3 aM and exhibited enormous potential in the fields of bioanalysis and clinical diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.analchem.1c04820 | DOI Listing |
Alzheimers Dement
December 2024
University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.
Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology and Neurological Sciences Stanford University School of Medicine, Stanford, CA, USA.
Dementia patients often received one clinical diagnosis, yet most of these cases present multiple underlying pathologies. Bringing the transition from clinical-based to biological-based diagnosis holds promise with the diagnostic criteria proposed by the Alzheimer's Association (AA) Revised Criteria for Diagnosis and Staging of Alzheimer's Disease and the Neuronal Synuclein Disease Integrated Staging System (NSD-ISS). This session aims to explore the practical implications of the AA revised criteria for diagnosing and designing clinical trials in Lewy body disease (LBD).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Background: Some types of cancer have been associated with reduced risk of clinical dementia diagnosis. Whether cancer history may be associated with neuropathological features of neurodegeneration or cerebrovascular disease is not well understood. We investigated the relation between cancer diagnosis and brain pathology in a sample of community-based research volunteers enrolled in an Alzheimer's Disease Research Center (ADRC) cohort.
View Article and Find Full Text PDFPreclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!